A 3D Bioprinted Spheroid Model of Nasopharyngeal Carcinoma Uncovers Constitutive IGF‑1R/PI3K/AKT Signaling as a Mediator of Intrinsic Cetuximab Resistance and a Therapeutic Vulnerability

Technical Summary: A 3D Bioprinted Spheroid Model of Nasopharyngeal Carcinoma Uncovers Constitutive IGF‑1R/PI3K/AKT Signaling as a Mediator of Intrinsic Cetuximab Resistance

Problem Statement
Nasopharyngeal carcinoma (NPC) is an aggressive malignancy endemic to Southern China and Southeast Asia, closely linked to Epstein–Barr virus infection. While concurrent chemoradiotherapy is standard for locally advanced cases, patients with recurrent or metastatic disease face poor prognosis, with a 5-year survival rate below 50%. A significant clinical challenge is the intrinsic resistance of approximately 40% of these patients to cetuximab, an EGFR-targeting monoclonal antibody. Unlike other solid tumors where resistance is often driven by canonical mutations (e.g., KRAS, BRAF), NPC exhibits extremely low mutation frequencies in these genes, suggesting that resistance is mediated by mutation-independent bypass signaling pathways. Furthermore, the mechanisms underlying this resistance remain incompletely elucidated, partly because conventional two-dimensional (2D) cell culture models fail to recapitulate the complex tumor microenvironment (TME), including hypoxic gradients, cell–matrix interactions, and spatial heterogeneity, leading to high false-positive rates in preclinical drug screening.

Methodology
To address the limitations of traditional models and investigate resistance mechanisms, the authors constructed a high-fidelity three-dimensional (3D) bioprinted spheroid model using the highly metastatic NPC cell line 5-8F.

• Model Construction: A dual-channel sequential deposition bioprinting technique was employed to mix Matrigel and cell suspension in situ within ultra-low attachment 96-well plates. This method allowed for precise control over spheroid architecture, size (80–100 µm), and uniformity, with minimal batch-to-batch variation.
• Experimental Design: Parallel 2D monolayer cultures served as controls. Cells were treated with cetuximab (10 µg/mL), the IGF-1R inhibitor OSI-906 (1 µM), or a combination of both for 48 hours.
• Assessment Metrics:
  • Viability and Apoptosis: Assessed via CCK-8 assays and Calcein-AM/PI live/dead staining.
  • Signaling Pathway Analysis: Western blotting was used to quantify the phosphorylation levels of IGF-1R (p-IGF-1R) and AKT (p-AKT), normalized to GAPDH.
  • Statistical Rigor: Experiments were performed with three biological replicates, and data were analyzed using one-way ANOVA.

Key Results

1. Intrinsic Cetuximab Resistance: Both 2D and 3D models confirmed that 5-8F cells are intrinsically resistant to cetuximab, showing no significant inhibition of cell viability across a concentration range of 0–40 µg/mL.
2. Superiority of the 3D Model: The 3D bioprinted spheroids more faithfully recapitulated in vivo characteristics, including hypoxic gradients and drug penetration dynamics. Drug responses and pathway alterations were more pronounced in the 3D model compared to 2D cultures. Live/dead staining revealed that while cetuximab had no effect, OSI-906 treatment induced significant cell death, particularly in the core regions of the spheroids.
3. Constitutive IGF-1R/PI3K/AKT Activation: Untreated 5-8F cells displayed constitutively high levels of p-IGF-1R and p-AKT. Cetuximab treatment failed to suppress this phosphorylation, confirming that EGFR inhibition does not block this survival axis.
4. Therapeutic Efficacy of OSI-906: Treatment with OSI-906, either as a monotherapy or in combination with cetuximab, significantly attenuated p-IGF-1R and p-AKT levels and inhibited cell proliferation. Notably, the combination therapy did not yield a statistically superior effect compared to OSI-906 monotherapy, suggesting that IGF-1R is the dominant upstream driver of AKT activation in this context.

Significance and Claims
The paper posits that the 3D bioprinted NPC spheroid model serves as a high-fidelity, reproducible, and high-throughput platform that bridges the gap between in vitro research and clinical settings. By overcoming the limitations of 2D cultures, this model provided the necessary physiological context to identify that constitutive activation of the IGF-1R/PI3K/AKT axis is a core mechanism underlying intrinsic cetuximab resistance in NPC.

The study claims that:

• This resistance is pre-existing and independent of EGFR mutations.
• Targeting IGF-1R with inhibitors like OSI-906 can effectively reverse this resistance phenotype.
• The 3D model is essential for accurately dissecting these mechanisms and screening therapeutic strategies, as it revealed drug response patterns (specifically the efficacy of OSI-906 in hypoxic cores) that were less apparent in 2D models.

The authors conclude that targeting IGF-1R represents a rational, precision therapeutic strategy for overcoming cetuximab resistance in recurrent/metastatic NPC, providing a strong experimental basis for future clinical development. The study acknowledges limitations, including the use of a single cell line and the need for in vivo validation, but emphasizes the immediate value of the model in elucidating resistance mechanisms and guiding targeted therapy design.